RS66013B1 - 3beta-(benziloksi)-17alfa-metil-pregn-5-en-20-on za upotrebu u lečenju kognitivnih poremećaja - Google Patents

3beta-(benziloksi)-17alfa-metil-pregn-5-en-20-on za upotrebu u lečenju kognitivnih poremećaja

Info

Publication number
RS66013B1
RS66013B1 RS20241106A RSP20241106A RS66013B1 RS 66013 B1 RS66013 B1 RS 66013B1 RS 20241106 A RS20241106 A RS 20241106A RS P20241106 A RSP20241106 A RS P20241106A RS 66013 B1 RS66013 B1 RS 66013B1
Authority
RS
Serbia
Prior art keywords
3bn17mep
cognitive
mice
disorders
compound
Prior art date
Application number
RS20241106A
Other languages
English (en)
Serbian (sr)
Inventor
Pier-Vincenzo Piazza
Sandy Fabre
Stéphanie Monlezun
Mathilde Metna
Monique Vallee
Jean-Michel Revest
Daniela Cota
Giovanni Marsicano
Aline Marighetto
Andrés Ozaita
Rafael Maldonado
Original Assignee
Aelis Farma
Univ Bordeaux
Institut National De La Sante Etde La Rech Medicale Inserm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aelis Farma, Univ Bordeaux, Institut National De La Sante Etde La Rech Medicale Inserm filed Critical Aelis Farma
Publication of RS66013B1 publication Critical patent/RS66013B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RS20241106A 2018-12-18 2019-12-18 3beta-(benziloksi)-17alfa-metil-pregn-5-en-20-on za upotrebu u lečenju kognitivnih poremećaja RS66013B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306716.4A EP3669876A1 (en) 2018-12-18 2018-12-18 3béta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders
EP19831675.4A EP3897655B1 (en) 2018-12-18 2019-12-18 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders
PCT/EP2019/085927 WO2020127468A1 (en) 2018-12-18 2019-12-18 3β-(BENZYLOXY)-17α-METHYL-PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS

Publications (1)

Publication Number Publication Date
RS66013B1 true RS66013B1 (sr) 2024-10-31

Family

ID=65278139

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20241106A RS66013B1 (sr) 2018-12-18 2019-12-18 3beta-(benziloksi)-17alfa-metil-pregn-5-en-20-on za upotrebu u lečenju kognitivnih poremećaja

Country Status (26)

Country Link
US (1) US12583884B2 (cg-RX-API-DMAC7.html)
EP (2) EP3669876A1 (cg-RX-API-DMAC7.html)
JP (1) JP7515480B2 (cg-RX-API-DMAC7.html)
KR (1) KR102845328B1 (cg-RX-API-DMAC7.html)
CN (1) CN113260366B (cg-RX-API-DMAC7.html)
AU (1) AU2019409912B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011654A2 (cg-RX-API-DMAC7.html)
CA (1) CA3118210C (cg-RX-API-DMAC7.html)
CL (1) CL2021001458A1 (cg-RX-API-DMAC7.html)
DK (1) DK3897655T3 (cg-RX-API-DMAC7.html)
ES (1) ES2987823T3 (cg-RX-API-DMAC7.html)
FI (1) FI3897655T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241376T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068626T2 (cg-RX-API-DMAC7.html)
IL (1) IL284032B2 (cg-RX-API-DMAC7.html)
LT (1) LT3897655T (cg-RX-API-DMAC7.html)
MA (1) MA54518B1 (cg-RX-API-DMAC7.html)
MD (1) MD3897655T2 (cg-RX-API-DMAC7.html)
MX (1) MX2021006904A (cg-RX-API-DMAC7.html)
PL (1) PL3897655T3 (cg-RX-API-DMAC7.html)
PT (1) PT3897655T (cg-RX-API-DMAC7.html)
RS (1) RS66013B1 (cg-RX-API-DMAC7.html)
SI (1) SI3897655T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400425T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020127468A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202103284B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021007382A (es) 2018-12-18 2021-07-15 Merck Sharp & Dohme Llc Derivados de pirimidona como agentes citotoxicos selectivos contra celulas infectadas por vih.
WO2024085245A1 (ja) 2022-10-21 2024-04-25 国立大学法人高知大学 術後せん妄の抑制薬

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004234125A1 (en) 2003-05-01 2004-11-11 Vernalis Research Limited Azetidinecarboxamide derivatives and their use in the treatment of CB1 receptor mediated disorders
ATE496894T1 (de) 2006-07-14 2011-02-15 Pfizer Prod Inc Tartratsalz von (7s)-7-ä(5-fluor-2-
CN101790521A (zh) 2007-06-28 2010-07-28 英特维特国际股份有限公司 作为cb1拮抗剂的取代哌嗪
CN106983754A (zh) 2011-05-20 2017-07-28 国家医疗保健研究所 Cb1受体拮抗剂
RU2667065C2 (ru) * 2012-11-28 2018-09-14 Энсэрм (Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль) Производные прегненолона
LT2976074T (lt) * 2013-03-19 2020-03-25 Universitat Pompeu-Fabra Kanabinoido receptoriaus cb1 antagonistai, skirti naudoti gydant ligas, susijusias su neuronų dendritų anomalijomis
IL276697B2 (en) 2018-02-20 2024-08-01 Aelis Farma 3beta-(4-methoxybenzyloxy)paragan-5-en-20-one for use in the treatment of cannabinoid-related disorders

Also Published As

Publication number Publication date
HUE068626T2 (hu) 2025-01-28
DK3897655T3 (da) 2024-09-23
IL284032A (en) 2021-08-31
CN113260366B (zh) 2024-03-08
HRP20241376T1 (hr) 2024-12-20
MA54518B1 (fr) 2024-11-29
AU2019409912A1 (en) 2021-05-27
JP7515480B2 (ja) 2024-07-12
PL3897655T3 (pl) 2025-01-13
KR102845328B1 (ko) 2025-08-12
IL284032B1 (en) 2025-01-01
EP3897655B1 (en) 2024-07-17
MD3897655T2 (ro) 2024-12-31
PT3897655T (pt) 2024-10-14
AU2019409912A8 (en) 2021-06-17
KR20210124962A (ko) 2021-10-15
US20220017562A1 (en) 2022-01-20
SI3897655T1 (sl) 2025-04-30
BR112021011654A2 (pt) 2021-09-08
WO2020127468A1 (en) 2020-06-25
CL2021001458A1 (es) 2022-01-21
EP3897655A1 (en) 2021-10-27
CA3118210A1 (en) 2020-06-25
MA54518A (fr) 2022-02-16
US12583884B2 (en) 2026-03-24
CA3118210C (en) 2024-05-21
SMT202400425T1 (it) 2024-11-15
CN113260366A (zh) 2021-08-13
JP2022515373A (ja) 2022-02-18
ES2987823T3 (es) 2024-11-18
FI3897655T3 (fi) 2024-09-17
ZA202103284B (en) 2024-09-25
LT3897655T (lt) 2024-10-10
AU2019409912B2 (en) 2025-02-20
MX2021006904A (es) 2021-09-30
EP3669876A1 (en) 2020-06-24
IL284032B2 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
Meneses 5-HT systems: emergent targets for memory formation and memory alterations
US12551474B2 (en) Use of pridopidine for the treatment of fragile X syndrome
Krasniak et al. The role of CHMP2BIntron5 in autophagy and frontotemporal dementia
Mangano et al. De novo GRIN2A variants associated with epilepsy and autism and literature review
NO327233B1 (no) Anvendelse av en glukokortikoidreseptorantagonist for fremstilling av et medikament til forbedring av psykose hos en pasient.
JP2009102343A (ja) ダウン症候群を有する成人において認知低下を阻害する方法
CN105744932A (zh) 用于治疗神经障碍的包含托拉塞米和巴氯芬的组合物
CA2871233A1 (en) Use of lurasidone for treating mental and behavioural disorders
JP2026031955A (ja) 自閉症スペクトラム障害の症状を治療する方法
CA3118210C (en) 3.beta.-(benzyloxy)-17.alpha.-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders
JP2003527342A (ja) 軽度認知障害を処置する方法
CN116075302A (zh) GABAAα5激动剂和SV2A抑制剂的组合以及在认知损害的治疗中的使用方法
RU2796005C2 (ru) 3β-(БЕНЗИЛОКСИ)-17α-МЕТИЛ-ПРЕГН-5-ЕН-20-ОН ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ КОГНИТИВНЫХ РАССТРОЙСТВ
Takahashi et al. Neurochemical and neuropharmacological characterization of ASP2905, a novel potent selective inhibitor of the potassium channel KCNH3
AU2017205162A1 (en) Tacrolimus for treating TDP-43 proteinopathy
HK40060558A (en) 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders
HK40060558B (en) 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders
WO2008008841A2 (en) Use of benzimidazole derivatives for the treatment and/or prevention of autoimmune disorders
WO2012040444A2 (en) Treatment of patients with incipient alzheimer's disease
Class et al. Patent application title: USE OF PRIDOPIDINE FOR THE TREATMENT OF FRAGILE X SYNDROME Inventors: Michael Hayden (Herzliya, IL) Mahmoud Abdulhossein Pouladi (Singapore, SG) Assignees: PRILENIA NEUROTHERAPEUTICS LTD. NATIONAL UNIVERSITY OF SINGAPORE Agency For Science, Technology and Research
Bellivier et al. GENETICS-Young Scientists Sessions/Oral Presentations
Holt et al. Hammersmith Hospital, London, 27-29 October 1988
HK40016661A (en) Pridopidine for use in the treatment of fragile x syndrome
Ralph Dopamine modulation of prepulse inhibition and locomotor behavior in knockout mice
Campbell et al. Inhibition of psychostimulant-induced hyperactivity responses in rats following oral administration of the metabotropic glutamate receptor 2/3 agonists, LY379268 and MGS0028